NCT03382405View on ClinicalTrials.gov

Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

November 13, 2017

Primary Completion Date

October 28, 2020

Study Completion Date

October 28, 2020

Conditions
Cytomegalovirus Infection
Interventions
BIOLOGICAL

mRNA-1647

Escalating dose levels

BIOLOGICAL

mRNA-1443

Escalating dose levels

OTHER

Placebo

Saline

Trial Locations (4)

33024

Research Centers of America, Hollywood

61614

Optimal Research, Peoria

66219

Johnson County Clinical Trials, Lenexa

83642

Advanced Clinical Research, Meridian

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY

NCT03382405 - Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults | Biotech Hunter | Biotech Hunter